Literature DB >> 33640027

The antinuclear antibody HEp-2 indirect immunofluorescence assay: a survey of laboratory performance, pattern recognition and interpretation.

Anne E Tebo1,2, Robert L Schmidt3,4, Kamran Kadkhoda5, Lisa K Peterson3,4, Edward K L Chan6, Marvin J Fritzler7, Mark H Wener8.   

Abstract

BACKGROUND: To evaluate the interpretation and reporting of antinuclear antibodies (ANA) by indirect immunofluorescence assay (IFA) using HEp-2 substrates based on common practice and guidance by the International Consensus on ANA patterns (ICAP).
METHOD: Participants included two groups [16 clinical laboratories (CL) and 8 in vitro diagnostic manufacturers (IVD)] recruited via an email sent to the Association of Medical Laboratory Immunologists (AMLI) membership. Twelve (n = 12) pre-qualified specimens were distributed to participants for testing, interpretation and reporting HEp-2 IFA. Results obtained were analyzed for accuracy with the intended and consensus response for three main categorical patterns (nuclear, cytoplasmic and mitotic), common patterns and ICAP report nomenclatures. The distributions of antibody titers of specimens were also compared.
RESULTS: Laboratories differed in the categorical patterns reported; 8 reporting all patterns, 3 reporting only nuclear patterns and 5 reporting nuclear patterns with various combinations of other patterns. For all participants, accuracy with the intended response for the categorical nuclear pattern was excellent at 99% [95% confidence interval (CI): 97-100%] compared to 78% [95% CI 67-88%] for the cytoplasmic, and 93% [95% CI 86%-100%] for mitotic patterns. The accuracy was 13% greater for the common nomenclature [87%, 95% CI 82-90%] compared to the ICAP nomenclature [74%, 95% CI 68-79%] for all participants. Participants reporting all three main categories demonstrated better performances compared to those reporting 2 or less categorical patterns. The average accuracies varied between participant groups, however, with the lowest and most variable performances for cytoplasmic pattern specimens. The reported titers for all specimens varied, with the least variability for nuclear patterns and most titer variability associated with cytoplasmic patterns.
CONCLUSIONS: Our study demonstrated significant accuracy for all participants in identifying the categorical nuclear staining as well as traditional pattern assignments for nuclear patterns. However, there was less consistency in reporting cytoplasmic and mitotic patterns, with implications for assigning competencies and training for clinical laboratory personnel.

Entities:  

Keywords:  Anti-nuclear antibodies; Cytoplasmic patterns; Indirect immunofluorescence; Mitotic patterns; Nuclear patterns; Performance survey

Year:  2021        PMID: 33640027      PMCID: PMC7916270          DOI: 10.1186/s13317-020-00146-w

Source DB:  PubMed          Journal:  Auto Immun Highlights        ISSN: 2038-0305


  3 in total

1.  Detection of antinuclear antibodies: comparative evaluation of enzyme immunoassay and indirect immunofluorescence methods.

Authors:  H A Homburger; Y D Cahen; J Griffiths; G L Jacob
Journal:  Arch Pathol Lab Med       Date:  1998-11       Impact factor: 5.534

2.  Guidelines for Antinuclear Antibody Testing.

Authors:  Allan S Wiik
Journal:  EJIFCC       Date:  2006-10-01

3.  Relationships among Antibodies against Extractable Nuclear Antigens, Antinuclear Antibodies, and Autoimmune Diseases in a Brazilian Public Hospital.

Authors:  Fernanda Weyand Banhuk; Bruna Corrêa Pahim; Alex Sandro Jorge; Rafael Andrade Menolli
Journal:  Autoimmune Dis       Date:  2018-09-30
  3 in total
  1 in total

1.  How to report the antinuclear antibodies (anti-cell antibodies) test on HEp-2 cells: guidelines from the ICAP initiative.

Authors:  Carlos Alberto von Mühlen; Ignacio Garcia-De La Torre; Maria Infantino; Jan Damoiseaux; Luis E C Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Minoru Satoh; Lucile Musset; Edward K L Chan
Journal:  Immunol Res       Date:  2021-10-09       Impact factor: 2.829

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.